evipedia.ai
← Back

Cerebroprotein Hydrolysate for Health & Longevity

Evidence Review created on 10/07/2026 using AI4L / Opus 5.5

Also known as: Cerebrolysin, Renacenz, Cerebrolysinum, FPF-1070, Cerebroprotein Hydrolysate-I, CH-I, Cerebrolysat, Cognistar, Brain Protein Hydrolysate

Motivation

Cerebroprotein hydrolysate (best known by the brand name Cerebrolysin) is a prescription medication made by breaking down purified pig brain proteins into very small protein fragments and amino acids. It is given by intravenous infusion or intramuscular injection, and it is thought to act like the brain’s own growth-supporting signals that help nerve cells survive and form new connections.

The preparation has been used for decades in parts of Europe, Russia and Asia for stroke, head injury and dementia, yet, as a literature review notes, it is not approved in the United States. In recent years it has drawn interest from people focused on brain health and healthy aging, who see it as a possible way to protect memory and thinking as they grow older. Its evidence base is debated, and much of it comes from studies supported by the company that makes it.

This review examines what is known about cerebroprotein hydrolysate for people seeking to preserve brain function over a long life: the evidence for and against its effects, its known and possible harms, how it is used in practice, and how its effects could be tracked.

Benefits - Risks - Protocol - Conclusion

These items give a high-level overview of cerebroprotein hydrolysate from supportive and critical perspectives.

Only four sources discuss cerebroprotein hydrolysate in enough depth to qualify, so four are listed. Among the priority experts, only Huberman Lab mentions Cerebrolysin, in a brief segment of a broader peptide episode with Dr. Craig Koniver; that segment is too short to stand as an overview and is cited under Therapeutic Protocol instead. No relevant content on cerebroprotein hydrolysate or Cerebrolysin was found from Peter Attia, Rhonda Patrick, Chris Kresser, Life Extension Magazine or Lifespan.io; their site searches and web searches returned no matching articles, episodes or posts.

Grokipedia

Cerebrolysin

An encyclopedic overview of composition, medical uses, dosing, clinical evidence, safety, regulatory status and controversies, useful as a quick orientation before the primary studies.

Examine

No Examine article on cerebroprotein hydrolysate or Cerebrolysin exists. Where it is approved, Cerebrolysin is a prescription medication, and Examine.com does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article on cerebroprotein hydrolysate or Cerebrolysin exists. Where it is approved, Cerebrolysin is a prescription medication, and ConsumerLab does not typically cover prescription medications.

Systematic Reviews

These systematic reviews and meta-analyses cover effects on stroke recovery, dementia and serious adverse events.

Mechanism of Action

Cerebroprotein hydrolysate is produced by enzymatic digestion of purified pig brain proteins into a mixture of low-molecular-weight peptides (short protein chains) and free amino acids (Ziganshina et al., 2023). Cerebrolysin, the reference product, is proposed to mimic the brain’s neurotrophic factors (nerve-growth-supporting proteins) such as BDNF (brain-derived neurotrophic factor, which supports neuron survival and learning) and NGF (nerve growth factor).

  • Neurotrophic signaling: a Chinese hydrolysate activated the PI3K/Akt pathway (a cell-survival signaling cascade) and reduced neuron death in mice (Wu et al., 2021).
  • Barrier protection: stroke patients showed less blood-brain barrier (protective vessel lining of the brain) leakage after two weeks (Khasanova & Kalinin, 2023).
  • Inflammation and growth signals: treatment lowered TNF-α (tumor necrosis factor alpha, an inflammatory signal) and raised IGF-1 (insulin-like growth factor 1, a growth signal) in Alzheimer’s patients in a manufacturer-coauthored trial (Alvarez et al., 2009).
  • Competing view: critics note no defined active ingredient and inconsistent clinical translation (Bereczki, 2017); several look-alike products lacked nerve-growth activity (Seidl & Aigner, 2024).
  • Pharmacology: as a mixture it has no single measurable half-life; peptides showed only transient blood exposure in rats (Zhang et al., 2024). EEG (electroencephalography, a recording of brain electrical activity) changes in healthy volunteers began within 15 minutes and lasted about 8 hours (Funke et al., 1998). Action is broad rather than selective, human brain uptake is unproven, and peptides are degraded by peptidases (protein-cutting enzymes); no cytochrome P450 (liver drug-metabolizing enzyme) studies exist.

Historical Context & Evolution

Cerebrolysin is an Austrian injectable brain-derived peptide preparation licensed for cerebrovascular disorders (diseases of the brain’s blood vessels), Alzheimer’s disease, vascular dementia, stroke and head injury (prescribing information), with about 30 years of clinical use in dementia (Gavrilova & Alvarez, 2021) and wide use in Russia, Eastern Europe and China (Ziganshina et al., 2023). Chinese manufacturers later produced cerebroprotein hydrolysates by similar extraction methods (Wu et al., 2021), and an oral derivative, N-PEP-12, was developed as a dietary supplement and tested for memory in healthy older adults in a manufacturer-coauthored study (Alvarez et al., 2005).

Early placebo-controlled dementia trials reported better clinician-rated global change, and some reported better cognitive scores (Plosker & Gauthier, 2009). In stroke, the manufacturer-supported, 1,070-patient CASTA trial found no difference on its main functional outcome, though severely affected patients showed a favorable trend (Heiss et al., 2012). A smaller manufacturer-coauthored trial combining Cerebrolysin with rehabilitation reported better arm function (Muresanu et al., 2016).

Opinion has since divided. Successive Cochrane reviews found no effect on death and, in 2023, a possible rise in non-fatal serious events (Ziganshina et al., 2023), while manufacturer-linked meta-analyses reported early neurological gains and comparable safety (Bornstein et al., 2018). A 2021 European neurology guideline endorsed it for early stroke rehabilitation (Beghi et al., 2021); its panel included investigators of manufacturer-supported trials, though neurologists derive no direct revenue from prescribing it. Healthy-aging interest came from its proposed nerve-growth effects and from self-experimenters; whether those effects extend to healthy brains remains open.

Expected Benefits

Most clinical evidence concerns Cerebrolysin, the reference cerebroprotein hydrolysate; most trials were supported by its manufacturer, EVER Neuro Pharma, and share company staff, investigators or a contract statistician, a conflict of interest that applies throughout this section.

High 🟩 🟩 🟩

No benefit reaches High: the replicated human trials of thinking and recovery come from one manufacturer-supported research network sharing staff and statisticians, and independent trials are few, small or measured different outcomes.

Medium 🟩 🟩

Thinking, memory and global function ⚠️ Conflicted

Cerebrolysin infusions improved cognition and global function in manufacturer-coauthored dementia trials (Gauthier et al., 2015; Guekht et al., 2011), though 30 and 60 mL failed on cognition in one (Alvarez et al., 2006); an independent meta-analysis found a small, low-certainty effect (Alsulaimani & Quinn, 2021). In mild cognitive impairment (memory decline short of dementia), courses outperformed vinpocetine (Gavrilova et al., 2010). Healthy adults received only oral N-PEP-12 (indirect evidence): memory (Crook et al., 2005) and attention (Chira et al., 2026) improved. Net: a small, short-term benefit, possibly below clinical relevance.

Magnitude: Cognition SMD (standardized mean difference, effect size in standard-deviation units) −0.16 (95% CI (confidence interval, the range likely to contain the true effect) −0.30 to −0.03) versus placebo across 8 trials; global function OR (odds ratio, the odds of improving compared between groups) 2.64 (95% CI 1.17 to 5.98) across 4 trials (Alsulaimani & Quinn, 2021).

Neurological and motor recovery after ischemic stroke ⚠️ Conflicted

Daily infusions started within 72 hours of ischemic stroke (stroke from a blocked artery), with rehabilitation, improved arm function at day 90 (Muresanu et al., 2016) and early neurological scores in a pooled analysis (Bornstein et al., 2018). The largest trial (1,070 patients) missed its primary functional endpoint (Heiss et al., 2012), as did a trial with clot-dissolving therapy (Lang et al., 2013); an independent six-trial meta-analysis found no day-90 benefit (Wang et al., 2017). Net: early neurological gains appear consistent, but lasting functional benefit is unconfirmed.

Magnitude: On the NIHSS (National Institutes of Health Stroke Scale, a stroke severity score), the Mann-Whitney effect size (probability that a treated patient does better than a placebo patient; 0.50 means no difference) was 0.60 versus placebo across nine trials (1,879 patients), with an NNT (number needed to treat for one extra patient to benefit) of 7.7 (95% CI 5.2 to 15.0) for clinically relevant early improvement (Bornstein et al., 2018).

Recovery after traumatic brain injury ⚠️ Conflicted

After moderate-to-severe traumatic brain injury, Cerebrolysin added to standard care improved a combined score of 13 function and thinking scales in one trial (Muresanu et al., 2020), while its companion trial missed significance in all randomized patients (Poon et al., 2020). Both come from one research network; a separate 32-patient trial in mild injury measured a different outcome (Chen et al., 2013). Net: a small-to-medium benefit, still resting largely on one network’s trials.

Magnitude: Mann-Whitney 0.60 (95% CI 0.52 to 0.68) versus placebo at day 90 across 185 patients in both trials, corresponding to SMD 0.34 (Vester et al., 2021); the companion trial alone gave 0.63 (95% CI 0.48 to 0.77).

Fewer bleeding complications after clot-dissolving stroke therapy

When Cerebrolysin was started alongside alteplase (a clot-dissolving drug) in a 341-patient open-label (unblinded) randomized trial, fewer patients developed symptomatic hemorrhagic transformation (bleeding into stroke-damaged brain that worsens symptoms) (Khasanova & Kalinin, 2023). Day-90 disability did not differ. This is a single unblinded trial from one Russian group.

Magnitude: Symptomatic bleeding 3.2% with Cerebrolysin versus 9.3% with alteplase alone, OR 0.248 (95% CI 0.072 to 0.851), NNT 16.3 (Khasanova & Kalinin, 2023).

Lower death rate after subarachnoid hemorrhage

After subarachnoid hemorrhage (bleeding into the space around the brain, usually from a burst blood vessel), Cerebrolysin added to standard care was linked to lower mortality in an independent meta-analysis of four studies with 530 patients (Kojder et al., 2023). The pooled studies were small and differed in dose, timing and design, and the authors note a lack of large randomized trials. One included randomized trial found no difference in cognitive performance at six months (Woo et al., 2020).

Magnitude: Mortality RR (risk ratio, the ratio of event risk between groups) 0.525 (95% CI 0.279 to 0.846) versus control across the pooled studies (Kojder et al., 2023).

Low 🟩

Speculative 🟨

Slowing brain aging processes

N-PEP-12 increased synapse density (nerve-cell connection points) in aged rats (Hutter-Paier et al., 2015); a Chinese hydrolysate raised telomerase (an enzyme protecting chromosome ends) in mice (Zhu et al., 2021). Animal data only.

Less Alzheimer-type brain pathology

In Alzheimer’s model mice, an oral hydrolysate reduced amyloid and tau (proteins that accumulate in Alzheimer’s) and markers of ferroptosis (iron-driven cell death) (Chen et al., 2023). The basis is animal data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: APOE4 (a gene variant that raises Alzheimer’s risk) findings conflict: non-carriers benefited more in two studies (Gavrilova et al., 2005; Selezneva et al., 2020), carriers in another (Gavrilova et al., 2010), and carriers’ larger BDNF rises tracked cognitive gains (Alvarez et al., 2016).
  • Baseline biomarkers: In advanced Alzheimer’s disease, higher serum VEGF (vascular endothelial growth factor, a blood-vessel growth signal) predicted larger gains from Cerebrolysin plus donepezil (Alvarez et al., 2020).
  • Severity of brain injury: Effects appear larger in moderate-to-severe stroke; a post hoc (after-the-fact) subgroup with severe stroke showed a favorable trend (Heiss et al., 2012), while mild cases may show little measurable gain.
  • Sex: No sex-based differences in benefit have been reported in the published trials.
  • Pre-existing conditions: Benefits were shown in people with stroke, head injury, dementia or mild cognitive impairment; in healthy adults, only indirect data from the oral derivative exist.
  • Age: Most trial participants were in their 60s and 70s; healthy-adult data cover ages 50 to 75 (Chira et al., 2026), with no data in the very old without disease.
  • Concurrent rehabilitation: A trial pairing infusions with structured rehabilitation showed large arm-function gains (Muresanu et al., 2016); no trial has compared Cerebrolysin with and without rehabilitation.

Potential Risks & Side Effects

Cerebrolysin’s tolerability data come mostly from older adults with stroke or dementia in manufacturer-supported trials; data in healthy users are minimal.

High 🟥 🟥 🟥

No risk reaches High: the serious-event signal comes from pooled acute-stroke trials that conflict with other pooled analyses, and severe reactions rest on product-information statements and case reports.

Medium 🟥 🟥

Blood pressure lowering at high doses

In a placebo-controlled trial in 48 healthy men given 10, 30 or 50 mL daily for 10 days, the 50 mL dose produced mild signs of overdosage and a small but significant fall in blood pressure (Funke et al., 1998). Effects were mild and caused no harm. Product information also lists rare low and high blood pressure in one study.

Magnitude: Direction: blood pressure fell versus placebo only at the 50 mL daily dose, not at lower doses; the published abstract reports no outcome figure (Funke et al., 1998).

Seizure provocation

In a retrospective cohort of 129 adults severely disabled after head injury, seizures were more frequent in the 65 patients given 10 mL Cerebrolysin daily for 30 days than in 64 matched patients not given it (Khalili et al., 2017). The study was observational, from a single center, and excluded people with earlier post-injury seizures. Product information contraindicates epilepsy and reports isolated grand mal seizures (generalized convulsive seizures).

Magnitude: Direction: seizures were more frequent with Cerebrolysin than without in the head-injury cohort (p = 0.042; p-value, the probability of a difference this large arising by chance alone); the published abstract reports no rates for either group (Khalili et al., 2017). Product information lists seizures as very rare, fewer than 1 in 10,000 patients (no control group).

Low 🟥

Transient infusion reactions and mood changes ⚠️ Conflicted

Product information lists rapid-injection dizziness and palpitations, agitation, insomnia and, in one study, depression and apathy. An open-label trial recorded more agitation (Khasanova & Kalinin, 2023), but trials of Cerebrolysin or similar peptide mixtures found no excess (Ziganshina et al., 2023). Net: mild, transient effects without confirmed excess over control.

Magnitude: Agitation 3.2% with Cerebrolysin versus 0.5% with standard care (open-label); total adverse events RR (risk ratio, the ratio of event risk between groups) 1.03 (95% CI 0.92 to 1.14) for Cerebrolysin or similar peptide mixtures versus placebo or no treatment across four trials.

Non-fatal serious adverse events ⚠️ Conflicted

The independent Cochrane review of acute-stroke trials found more non-fatal serious adverse events with Cerebrolysin (Ziganshina et al., 2023). A larger twelve-trial analysis by manufacturer-trial investigators (Strilciuc et al., 2021) and dementia trials found no excess. Net: an unresolved signal in acutely ill patients, untested in healthy users.

Magnitude: Non-fatal serious events RR 2.39 (95% CI 1.10 to 5.23) versus placebo across three stroke trials (1,335 patients) (Ziganshina et al., 2023); serious events in dementia trials RR 0.96 (95% CI 0.78 to 1.18) versus control (Alsulaimani & Quinn, 2021).

Severe allergic reactions

Life-threatening anaphylaxis (a rapid, whole-body allergic reaction) after intravenous Cerebrolysin was documented in an 85-year-old stroke patient and confirmed by laboratory tests (Trimmel et al., 2024). Product information lists hypersensitivity, including shock-like states, as very rare.

Magnitude: Very rare, fewer than 1 in 10,000 patients, per product information (Polish product information) (no control group).

Speculative 🟨

Contamination and infection with unregulated products

Gray-market vials and home injection add risks of contamination, infection and mislabeled content; look-alike products differ in composition (Seidl & Aigner, 2024). The basis is mechanistic only.

Animal-tissue pathogen transmission

Brain-derived animal products carry a theoretical risk of transmitting animal pathogens or prions (misfolded infectious proteins). No human cases are reported; the basis is mechanistic only.

Risk-Modifying Factors

  • Genetic polymorphisms: No study has linked gene variants to adverse effects, and no metabolizing enzymes with known variants are involved.
  • Baseline kidney function: Severe renal impairment (severely reduced kidney function) is a contraindication (prescribing information); the amino-acid and peptide load is cleared partly by the kidneys.
  • Allergy history: Allergic diseases call for special caution (Polish product information), and prior reactions to pig-derived products raise anaphylaxis concern.
  • Sex: No sex-based differences in adverse events have been reported.
  • Pre-existing conditions: Epilepsy, therapy with antidepressants or MAO inhibitors (monoamine oxidase inhibitors, older antidepressants), and acute ischemic stroke, where the serious-event signal arose, raise risk.
  • Age: Trial participants were mostly older adults; the documented anaphylaxis occurred at 85, and product information notes that reported effects are common in elderly people anyway.
  • Infusion rate: Too-rapid injection causes dizziness, palpitations and flushing (Polish product information).

Key Interactions & Contraindications

  • Antidepressants (sertraline, escitalopram, amitriptyline): Caution. Product information warns of possible additive effects, plausibly excess activation such as agitation or insomnia (theoretical), and advises reducing the antidepressant dose (Polish product information).
  • MAO inhibitors (phenelzine, tranylcypromine, selegiline): Caution. Product information lists concurrent use as a special warning because of possible additive effects, plausibly excess activation such as agitation or insomnia (theoretical); antidepressant dose reduction is advised.
  • Balanced amino-acid infusion solutions (intravenous nutrition mixtures): Do not mix in one infusion, per product information; risk of incompatibility.
  • Vitamins and cardiovascular drugs (e.g., metoprolol, amiodarone): Caution (mixing only): may be given concurrently, but not mixed in the same syringe, per product information; consequence is physical incompatibility.
  • Clot-dissolving drugs (alteplase): No interaction found; a placebo-controlled trial found no excess adverse events (Lang et al., 2013), and an open-label trial found no safety concerns beyond more mild agitation (Khasanova & Kalinin, 2023). Monitor as for clot-dissolving treatment alone.
  • Cholinesterase inhibitors (dementia drugs that boost acetylcholine; donepezil, rivastigmine): No interaction found for donepezil; a randomized trial found the combination safe (Alvarez et al., 2011). Rivastigmine is unstudied; none expected (theoretical).
  • Over-the-counter medications (ibuprofen, acetaminophen, diphenhydramine): No interaction reported; none expected (theoretical). Sedating antihistamines could mask agitation or dizziness; monitor.
  • Serotonergic (serotonin-raising) supplements (St. John’s wort, 5-hydroxytryptophan, S-adenosylmethionine): Caution (theoretical): by analogy with the antidepressant warning, additive mood or activation effects are possible.
  • Additive nootropic (cognition-enhancing) supplements and peptides (citicoline, Lion’s Mane, Semax): Monitor (theoretical): overlapping activating or nerve-growth effects could add agitation or insomnia.
  • Structured motor rehabilitation: No safety concern; potentiating: a stroke trial showed benefit when infusions accompanied structured rehabilitation (Muresanu et al., 2016).

Populations who should avoid Cerebroprotein Hydrolysate:

  • People with hypersensitivity to any component of the drug (prescribing information)
  • People with epilepsy, especially grand mal seizures (Polish product information)
  • People with severe renal impairment, defined in a manufacturer-sponsored trial’s exclusion criteria as eGFR (estimated glomerular filtration rate, a calculated kidney-function measure) below 30 mL/min/1.73 m² (NCT05755997)
  • Pregnant or breastfeeding women, except after careful risk-benefit assessment, as no human data exist (Polish product information)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Slow, diluted infusion: Doses above 10 mL are given diluted, over 15 to 60 minutes (Polish product information); prevents dizziness, palpitations and flushing from too-rapid injection.
  • Supervised first dose: The first infusion given in a clinic with 30 minutes of observation and epinephrine on hand mitigates severe allergic reactions.
  • Stop at allergy signs: Itching, rash, breathlessness or chills during infusion are reasons to stop and seek medical care, limiting anaphylaxis progression.
  • Seizure screening: Excluding people with epilepsy before a course prevents seizure provocation, per product contraindications.
  • Antidepressant review: Reviewing antidepressant or MAO inhibitor doses with the prescriber before a course mitigates additive mood and activation effects, per product information.
  • Moderate dosing: Staying at or below 30 mL daily avoids the blood-pressure fall seen at 50 mL in healthy volunteers (Funke et al., 1998).
  • Verified sourcing: Using pharmacy-supplied, batch-numbered ampoules from the license holder prevents contamination and ineffective look-alike products.
  • Sterile clinical administration: Infusions given by trained staff with sterile technique reduce injection-site infection and vein irritation.
  • Mood check: Tracking mood for two days after each course detects the depression or apathy that product information lists, prompting dose reduction or discontinuation.
  • Kidney check: A baseline creatinine test with eGFR identifies severe renal impairment (eGFR below 30 mL/min/1.73 m², per NCT05755997), a contraindication, before starting.

Therapeutic Protocol

Other parameters without a citation (timing, cycling, titration) reflect common practice.

  • Product label regimen: For mild organic (brain-damage-related) and dementia syndromes, 5 to 30 mL daily for 10 to 20 days; courses repeated while improving, with a break equal to course length (Polish product information).
  • Routes: Up to 5 mL intramuscularly, up to 10 mL undiluted intravenously, and 10 to 50 mL as a diluted infusion (Polish product information).
  • Dementia trial regimen: 10 mL intravenously five days weekly for four weeks, then twice weekly; only 10 mL significantly improved cognition versus placebo (Alvarez et al., 2006).
  • Vascular dementia regimen: 20 mL intravenously daily in two treatment cycles (Guekht et al., 2011).
  • Stroke rehabilitation regimen: 30 mL intravenously daily for at least 10 days, per a European guideline (Beghi et al., 2021); its panel included investigators of manufacturer-supported trials, though neurologists derive no direct revenue from prescribing it.
  • Practitioner use: Dr. Craig Koniver (Koniver Wellness, Charleston and London) reported giving Cerebrolysin intravenously or subcutaneously, then largely stopping because patients felt low for a day or two; he gave no dose (Huberman Lab).
  • Oral derivative: N-PEP-12 at 45 or 90 mg daily for 180 days in healthy older adults (Chira et al., 2026).
  • Time of day: Morning or early-day infusions are preferred because activation, agitation and insomnia are listed effects.
  • Half-life: No single half-life exists; peptides circulate only briefly, while EEG effects lasted about 8 hours after 10 mL (Funke et al., 1998).
  • Single versus split dosing: All studied regimens use one daily administration; splitting has not been studied.
  • Genetic polymorphisms: APOE4 status changed clinical response in dementia and mild cognitive impairment studies, in conflicting directions (Gavrilova et al., 2005; Gavrilova et al., 2010); no study has tested genotype-guided dosing.
  • Sex: No sex-based dosing differences have been reported.
  • Age: Trials enrolled mainly adults in their 60s and 70s; older adults may warrant lower starting doses and slower infusions.
  • Baseline biomarkers: Higher baseline VEGF predicted greater response in advanced Alzheimer’s disease (Alvarez et al., 2020); no marker guides use in healthy adults.
  • Pre-existing conditions: Kidney disease, epilepsy and allergic disorders change suitability; stroke and dementia regimens differ in dose.

Discontinuation & Cycling

  • Course-based use: Cerebroprotein hydrolysate is used in short courses, not as lifelong daily therapy; courses may be repeated while improvement continues (Polish product information).
  • Withdrawal effects: No withdrawal syndrome has been reported after stopping a course.
  • Tapering: No tapering is needed; trial regimens simply reduce frequency, for example from daily to two or three times weekly.
  • Cycling: Cycling is built into labeled use: a treatment-free interval equal to the course length separates courses.

Sourcing and Quality

  • Reference product: Cerebrolysin from EVER Neuro Pharma (Austria) is the licensed, most-studied product, sold by prescription in approving countries (prescribing information) in ampoules such as 1, 5 and 10 mL.
  • Look-alike products: Products sold as equivalents, including Cognistar (labeled cerebroprotein hydrolysate), showed no functional benefit in a blinded rat stroke comparison (Zhang et al., 2019); clinical data for one product do not transfer to another.
  • Gray market: Vendors selling “research” vials without prescriptions offer no assurance of identity, sterility or potency; batch numbers and pharmacy origin are the main quality markers.
  • Third-party testing: No independent consumer testing of these products exists; ConsumerLab and Examine do not cover them.
  • Storage: Ampoules are stored at 15 to 25 °C (Polish product information); cloudy or discolored solutions are discarded.
  • Oral derivative: N-PEP-12 is sold as a dietary supplement (Alvarez et al., 2005); supplement manufacturing standards apply rather than drug standards.

Practical Considerations

  • Time to effect: Dementia trials showed global changes after four weeks of infusions (Gauthier et al., 2015); a stroke trial measured arm-function gains at 90 days (Muresanu et al., 2016); healthy-adult attention changes appeared by 90 days (Chira et al., 2026).
  • Common pitfalls: Assuming disease-trial benefits transfer to healthy brains, buying unverified vials, injecting too fast, and using larger doses although only 10 mL significantly improved cognition in one dementia trial (Alvarez et al., 2006).
  • Regulatory status: Prescription medication in Austria (prescribing information), Poland (Polish product information) and other countries; not approved for use in the United States (Fiani et al., 2021).
  • Access and cost: Courses require repeated infusions by trained staff, typically paid out of pocket outside approving countries, making access effortful and costly.
  • Payer incentives: A provider-perspective cost-effectiveness analysis by investigators of the head-injury trial it modeled judged Cerebrolysin likely cost-effective (Strilciuc et al., 2025); no independent payer analysis was found, a possible source of structural bias.

Interaction with Foundational Habits

  • Sleep: Direct, potentially disruptive: product information lists insomnia within its activation effects. Morning infusions and keeping regular sleep timing during courses reduce this; no study has measured sleep quality as an outcome.
  • Nutrition: No direct interaction: the product supplies amino acids in amounts too small to matter nutritionally. No foods need avoiding, no nutrient depletion is reported, and infusions can be given regardless of meals.
  • Exercise: Potentiating: a stroke trial paired infusions with daily structured rehabilitation and saw larger motor gains than rehabilitation with placebo (Muresanu et al., 2016). Scheduling training sessions on infusion days mirrors that design; no study shows blunting of exercise adaptations.
  • Stress management: Indirect: transient low mood or agitation after courses has been reported, and antidepressant effects may be additive. Scheduling courses during low-stress periods and tracking mood helps separate drug effects from life stress.

Monitoring Protocol & Defining Success

Before starting, a baseline assessment documents kidney function, allergy and seizure history, current antidepressant or MAO inhibitor use, seated blood pressure, and a standardized cognitive test such as the MoCA (Montreal Cognitive Assessment, a 30-point screening test of thinking). Mood and sleep are recorded for one week beforehand to give a personal reference point.

Ongoing monitoring follows a set cadence: blood pressure before and after each infusion; mood and sleep daily during each course and for two days after; the cognitive test at the end of each course and again 3 months later; and creatinine before each new course or every 6 to 12 months. Success is defined as a sustained improvement on repeated cognitive testing relative to one’s own baseline, without adverse effects. Absence of change after two courses suggests no personal benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine 0.7–1.3 mg/dL in men, 0.6–1.1 mg/dL in women (standard reference range) Safety check: severe renal impairment stops use Morning sample; pair with eGFR (estimated glomerular filtration rate, a calculated kidney-function measure); hydration affects results
Blood pressure No established target; track change from the pre-infusion reading Safety check: falls occurred at 50 mL in volunteers Measure seated before and 15 minutes after infusion; relevant for people on blood-pressure drugs
MoCA score No established target; track change from the individual’s own baseline Marker expected to change: cognition improved in dementia trials Use alternate test versions to limit practice effects; test at the same time of day
Serum IGF-1 Age- and sex-specific laboratory range (standard reference range) Marker expected to change: rose in Alzheimer’s patients on treatment Fasting morning sample; trial evidence is from Alzheimer’s patients (Alvarez et al., 2009)

Qualitative markers:

  • Mood stability, especially one to two days after each course
  • Sleep quality and sleep onset during courses
  • Mental clarity, word-finding and everyday memory
  • Agitation, restlessness or irritability
  • Injection-site comfort and any allergic symptoms

Emerging Research

  • Small-vessel brain disease trial: A crossover (each participant receives drug and placebo in turn) phase 2 trial in 30 people with CADASIL (an inherited small-vessel brain disease) tests cognition and white-matter lesions (damaged brain wiring) (NCT05755997), active, not recruiting, completing December 2026. Positive results would strengthen the vascular-aging rationale; null results would weaken it.
  • After clot retrieval: A 100-patient phase 2 trial in Taiwan tests Cerebrolysin after late-window thrombectomy (catheter clot removal), with infarct volume (size of the dead brain tissue) as the primary endpoint (NCT06339411), not yet recruiting, completion 2030. Positive results would support brain protection; null results would weaken the barrier-protection claim.
  • Post-stroke aphasia: A 40-patient placebo-controlled phase 4 trial tests language recovery in non-fluent aphasia (impaired speech production) (NCT06897176), completion 2027. Positive results would extend recovery benefits to language; null results would narrow them.
  • Delirium in intensive care: A 500-patient study of delirium (acute confusion) (NCT06677502) passed its registered December 2025 completion date; status remains “enrolling by invitation,” with no results posted. Positive results would extend acute brain benefits to confusion states; null results would narrow them.
  • Real-world stroke registry: A 1,769-patient comparative registry reported better 90-day function with Cerebrolysin (Vosko et al., 2025), but non-randomized design and manufacturer links leave confounding (other differences between the groups explaining the result) possible; a large independent randomized trial could confirm or overturn it.
  • Healthy aging: The 2026 N-PEP-12 trial in healthy older adults (Chira et al., 2026) awaits independent replication; a null replication would remove the only human signal in healthy brains.
  • Safety reassessment: The Cochrane non-fatal serious-event signal (Ziganshina et al., 2023) could be confirmed or refuted by independent trials reporting serious events in full.

Conclusion

Cerebroprotein hydrolysate, best known as Cerebrolysin, is a prescription mixture of small protein fragments and amino acids made from pig brain and given by repeated infusion or injection. For people seeking to protect brain function over a long life, its appeal lies in its proposed ability to mimic the brain’s own growth signals.

The strongest human evidence comes from people who already have brain disease. In dementia, stroke recovery and head injury, studies point to small improvements in thinking and early recovery, but large trials have also come up empty, and independent reviewers judge the overall certainty to be low. Most studies were funded or run with the manufacturer, and a European guideline endorsing it was written partly by those studies’ investigators, though neurologists earn nothing directly from prescribing it; this conflict of interest colors much of the evidence. For healthy adults, the only human data come from an oral relative of the drug, with modest effects on attention and memory.

Most side effects are mild and short-lived, such as dizziness, flushing and restlessness, especially with fast infusion. Rare severe allergic reactions occur, the product information excludes epilepsy and serious kidney disease, and one independent review found more serious but non-fatal medical problems in stroke patients, a finding other analyses did not reproduce.

Overall, the evidence shows a plausible but modest and contested effect in damaged brains, and an essentially untested one in healthy aging brains.

Top - Benefits - Risks - Protocol